Bystolic (nebivolol) / Menarini, AbbVie - LARVOL DELTA

Third Generation Beta-Blocker and Tacrolimus Effects on Renal Function, and Vasodilator Nitric Oxide Levels of Kidney Transplant Recipients: A Secondary Stratified Analysis (WTC 2025) - "Among KTRs, tacrolimus is associated with a trend of lower delta-NO and delta-GFR in percentile distributions of each outcome. Nebivolol has diverging associations with delta-NO and delta-GFR. The interaction between nebivolol and tacrolimus is negatively associated with more delta-NO than delta-GFR percentile distributions."

Clinical • Cardiovascular • Hypertension • Transplantation

Impact of Nebivolol versus Carvedilol on long-term outcomes on long-term clinical outcomes in ST-elevation myocardial infarction patients with mid-range left ventricular ejection fraction (40% to 49%) (ESC-WCC 2025) - No abstract available

Clinical • Clinical data • Cardiovascular • Myocardial Infarction

Impact of beta-blocker nebivolol versus carvedilol prescription at discharge on long-term clinical outcomes in STEMI patients with reduced LVEF treated with drug-eluting stents (ESC-WCC 2025) - No abstract available

Clinical • Clinical data • Acute Coronary Syndrome • Cardiovascular

Impact of nebivolol versus bisoprolol on long-term clinical outcomes in STEMI patients treated with drug-eluting stents (ESC-WCC 2025) - No abstract available

Clinical • Clinical data • Cardiovascular

Impact of nebivolol versus carvedilol on long-term clinical outcomes in STEMI patients treated with drug-eluting stents (ESC-WCC 2025) - No abstract available

Clinical • Clinical data • Cardiovascular

Impact of beta-blocker Nebivolol versus Carvedilol prescription at discharge on long-term clinical outcomes in STEMI patients with preserved LVEF treated with drug-eluting stents (ESC-WCC 2025) - No abstract available

Clinical • Clinical data • Acute Coronary Syndrome • Cardiovascular

RaP-AF: Rate Control in Patients With Atrial Fibrillation (clinicaltrials.gov) - P=N/A | N=50 | Active, not recruiting | Sponsor: National Taiwan University Hospital | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Jun 2022 ➔ Dec 2026

Enrollment closed • Trial completion date • Atrial Fibrillation • Cardiovascular

Targeting fibrosis and steatosis: Nebivolol multi-pathway modulator ameliorates experimental non-alcoholic steatohepatitis in rats through AMPK/mTOR and TGF-β1/α-SMA pathways. (PubMed, Bioorg Chem) - "Nebivolol exerts a multi-targeted hepatoprotective effect against NASH, mainly mediated through the modulation of AMPK/mTOR and TGF-β1/α-SMA pathways, besides restoration of NO and eNOS signaling. These findings highlight Nebivolol as a promising candidate for the management of NASH and related liver disorders."

Journal • Preclinical • Addiction (Opioid and Alcohol) • Fibrosis • Hepatology • Immunology • Metabolic Dysfunction-Associated Steatohepatitis • Oncology • BECN1 • IL1B • mTOR • NOS3 • PPARA • TGFB1

Urinary Bladder Paraganglioma With POT1 and RECQL4 Mutations Almost Missed by Ga-68 DOTATATE PET/CT (ENDO 2025) - "Spironolactone therapy improved blood pressure (BP) control; however, BP spikes continued along with headaches occasionally associated with voiding/bowel movements. Medications were amlodipine 10 mg/day, eplerenone 50 mg BID, nebivolol 5 mg/day, doxazosin 2 mg nightly... Bladder paragangliomas pose a diagnostic challenge. As illustrated in this case, Ga68-DOTATATE PET/CT initially missed this lesion due to the urinary excretion of the tracer highlighting the need for other imaging modalities when considering bladder PGLs. Further studies examining whether POT1 or REQL4 mutations might be pathogenic for (urinary) PGLs are warranted."

Bladder Cancer • Cardiovascular • Colonic Polyps • Endocrine Cancer • Endocrine Disorders • Follicular Lymphoma • Gastroenterology • Hematological Malignancies • Hodgkin Lymphoma • Hypertension • Lymphoma • Neuroendocrine Tumor • Oncology • Pain • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • POT1 • RECQL4 • SDHB • SYP • TP63

Development and validation of an ADRβ1-SNAP-tag/CMC model for screening ADRβ1 antagonists: Application to nebivolol and its byproducts. (PubMed, J Pharm Biomed Anal) - "In vitro calcium influx experiments verified the interaction of these components with ADRβ1, showing good inhibitory effects on ADRβ1. In conclusion, the ADRβ1 SNAP-tag/CMC model developed in this study can be used for the comprehensive screening of active components targeting ADRβ1 in complex samples."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Hirata Syndrome in a Woman With Graves' Disease Without Exposure to Thionamides and Summary of Cases from South America. (PubMed, JCEM Case Rep) - "Six months before admission, both arterial hypertension and Graves' disease were disclosed, receiving nebivolol 5 mg day only...Treatment of hypoglycemia included drug withdrawal, a fractionated diet with low-glycemic index carbohydrates, prednisone, and radioactive iodine for definitive treatment of Graves' disease, with resolution of the condition 6 months later...We did not identify any trigger factor for hypoglycemia besides Graves' disease as she did not receive any drug at hypoglycemia onset. We recommend checking for anti-insulin antibodies in cases of endogenous hyperinsulinism associated with an autoimmune disease, despite the absence of any drug treatment."

Journal • Cardiovascular • Endocrine Disorders • Grave’s Disease • Hypertension • Hypoglycemia • Immunology • Pulmonary Arterial Hypertension • Severe Hypoglycemia

Nebivolol restores the anticontractile effect of mesenteric perivascular adipose tissue lost due to obesity. (PubMed, Eur J Pharmacol) - "Overall, our results revealed that nebivolol reversed the obesity-induced loss of the anticontractile effect of the mPVAT by promoting antioxidant and anti-inflammatory effects. Hence, nebivolol represents a powerful pharmacological tool in addressing cardiovascular dysfunctions induced by obesity."

Journal • Cardiovascular • Genetic Disorders • Hypertension • Obesity • Pulmonary Arterial Hypertension • IL1B • IL6 • LEP • TNFA

The overlooked consequence of beta-blockers: impaired platelet function (ISTH 2025) - "They act on the beta-adrenergic receptors (B1, B2, and B3), thereby preventing the effects of epinephrine and norepinephrine...Beta-blockers, particularly Nebivolol, reduce the risk of thrombosis by decreasing platelet activation, a desirable effect in some instances but can increase the risk of bleeding as evidenced in this case...He did not present with anymore bleeding after the discontinuation of Nevibolol. Table or Figure Upload"

Anemia • Cardiovascular • Hematological Disorders • Hypertension • Thrombosis

Differential Effects of Antihypertensive Drugs on Central Blood Pressure: A Randomized Comparison between Nebivolol and Telmisartan. (PubMed, Am J Hypertens) - "Nebivolol was less effective than telmisartan at reducing cSBP."

Journal • Cardiovascular • Hypertension

Calcium triggers calmodulin degradation to induce EGF receptor instability and overcome non-small cell lung cancer resistance to tyrosine kinase inhibitors. (PubMed, J Biol Chem) - "Notably, a combination of Ca2+ activator curcumin, FBXL2 activator nebivolol, and osimertinib significantly inhibits EGFRT790M/C797S-driven TKI-resistant NSCLC growth. Together, this study highlights the importance of the negative feedback loop between Ca2+ and CaM and the critical regulatory role of Ca2+/CaM in the FBXL2-mediated EGFR degradation, providing a viable therapeutic strategy for TKI-resistant NSCLC."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • FBXL2

Advanced eco-friendly spectrophotometric analysis for Nebivolol, Valsartan, and related impurity with comprehensive environmental impact assessment. (PubMed, Sci Rep) - "The proposed methods were validated as per ICH guidelines and verified to be accurate. Statistical analysis was performed to ensure the validity of methods concerning published methods."

Journal

Predictors of graft patency following coronary artery bypass graft surgery: the role of nebivolol therapy. (PubMed, Geroscience) - "Nebivolol has been found to reduce the frequency of graft occlusion following CABG, especially in case of SVG grafts. The vasodilatory properties of nebivolol may, at least in part, be responsible for the favorable effects of the drug to prevent graft occlusion."

Journal • Cardiovascular • Peripheral Arterial Disease

ARTEMISIA: Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients (clinicaltrials.gov) - P4 | N=266 | Completed | Sponsor: Menarini International Operations Luxembourg SA | Recruiting ➔ Completed

Trial completion • Cardiovascular • Hypertension

Prospective Observational Study On The Impact Of Nebilet In Blood Pressure Control In Hypertensive Patients (HYIMPACT) (clinicaltrials.gov) - P=N/A | N=4537 | Recruiting | Sponsor: A.Menarini Asia-Pacific Holdings Pte Ltd

New trial • Cardiovascular • Hypertension

In vitro-in vivo scaling of cytochrome P450-mediated metabolic clearance using a relative activity factor approach. (PubMed, Drug Metab Dispos) - "We selected multiple probe substrates for CYP1A2 (caffeine, tizanidine, phenacetin), CYP2C9 ((S)-acenocoumarol, glimepiride, lornoxicam, tolbutamide, (S)-warfarin), CYP2C19 ((S)-lansoprazole, omeprazole, pantoprazole), CYP2D6 (desipramine, metoprolol, nebivolol, tolterodine), and CYP3A4 (alprazolam, felodipine, midazolam, nisoldipine, sildenafil, triazolam) to calculate the representative RAF value for each P450 isoform based on the in vivo-to-in vitro clearance ratio of the multiple probe substrates...The fm values of the responsible P450 isoform(s) could be well predicted for mexiletine, tamsulosin, risperidone, celecoxib, and glibenclamide...By applying relative activity factor values obtained from multiple probe substrates, this study was able to quantitatively predict the in vivo clearances mediated by CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. This simple, practical method will help optimize metabolic clearances via the major cytochrome P450..."

Journal • Preclinical • CYP1A2 • CYP2C19 • CYP2C9 • CYP3A4

DANBLOCK: Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction (clinicaltrials.gov) - P4 | N=2760 | Active, not recruiting | Sponsor: Bispebjerg Hospital | Trial completion date: Apr 2025 ➔ Dec 2035

Trial completion date • Cardiovascular • Congestive Heart Failure • Myocardial Infarction

A CASE REPORT OF SWALLOWING INDUCED ATRIAL TACHYCARDIA - Travis Hanson (ACC 2025) - "This 46-year-old male with palpitations, intermittent chest pain, and lightheadedness while swallowing was diagnosed with SIAT. The patient's symptoms have been well managed with metoprolol and diltiazem."

Case report • Clinical • Cardiovascular • Pain

EFFICACY OF NEBIVOLOL/VALSARTAN COMBINED PILL FOR ANTI-HYPERTENSIVE THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS - Talal Warsi (ACC 2025) - "The N/V combination pill significantly reduces systolic blood pressure SBP in comparison to valsartan, valsartan/amlodipine, or nebivolol, and DBP relative to nebivolol. However, it is important to consider limitations such as small sample size, lack of gender-specific data, and unreported adverse effects. Further comprehensive studies are needed to support the safety and effectiveness of N/V combination pills in different demographic subgroups."

Retrospective data • Review • Cardiovascular • Hypertension

Nebivolol rescued the liver and kidney from the coadministration of rivaroxaban and cisplatin by targeting inflammation, oxidative stress, and apoptosis in rats. (PubMed, Int Immunopharmacol) - "Moreover, nebivolol lowered the levels of caspase-3 in the liver and NF-κB in the kidneys. In conclusion, our study indicates that nebivolol protects the liver and kidneys from the detrimental effects of cisplatin and rivaroxaban."

Journal • Preclinical • Hepatology • Inflammation • Liver Failure • Oncology • Solid Tumor • CASP3 • IL6 • NFKB1 • TNFA

Mechanisms of nebivolol-mediated effects on bFGF-induced vascular smooth muscle cell proliferation and migration. (PubMed, Curr Res Pharmacol Drug Discov) - "The enhancement on bFGF-induced cell proliferation at lower concentrations appears to be mainly mediated by activation of β3-ARs but the inhibitory effects on bFGF-mediated cell proliferation as well as migration may occur through different mechanisms. AKT signaling is only involved in high concentrations of nebivolol-mediated effects."

Journal